Skip to main content
Fig. 1 | Malaria Journal

Fig. 1

From: Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial

Fig. 1

Clinical outcome by treatment and CYP2D6 status. Relapse frequency is the percentage (%) of subjects who experienced a relapse, with error bars representing the standard error of the mean. Odds ratios (ORs) and 95 % confidence intervals (95 % CI) were from analyses comparing the relapse frequency of reduced metabolizers (IMs) with that of extensive metabolizers (EMs) within each treatment group. Exact logistic regression was used to derive ORs, except for the TQ high dose arm (TQ 300 mg/TQ 600 mg), in which Fisher’s Exact test was used with a correction of 0.05 to each cell as there were no IM subjects who relapsed. One-sided p values (p) are displayed (see “Methods” section)

Back to article page